Combination therapy with braf inhibitors for the treatment of cancer

Combining BRAF inhibitors with Omomyc variants and encoding polynucleotides addresses the limitations of current cancer treatments by enhancing therapeutic efficacy and specificity, offering improved cancer therapy options.

HK40134781APending Publication Date: 2026-07-10FUNDACIO PRIVADA INST DINVESTIGACIO ONCOLOGICA DE VALL DHEBRON (VHIO) +1
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
FUNDACIO PRIVADA INST DINVESTIGACIO ONCOLOGICA DE VALL DHEBRON (VHIO)
Filing Date
2026-05-12
Publication Date
2026-07-10

AI Technical Summary

Technical Problem

Current treatments for cancer, particularly those targeting BRAF mutations, often face limitations in efficacy and specificity, leading to resistance and limited therapeutic options.

Method used

Combining BRAF inhibitors with Omomyc or functionally equivalent variants, along with polynucleotides encoding these peptides, to enhance treatment efficacy and specificity against cancer cells.

Benefits of technology

The combination therapy improves treatment outcomes by increasing sensitivity and selectivity of cancer therapies, overcoming resistance and providing new therapeutic avenues.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000072_0000
    Figure 00000072_0000
  • Figure 00000072_0001
    Figure 00000072_0001
  • Figure 00000073_0000
    Figure 00000073_0000
Patent Text Reader

Abstract

The invention relates to a combination of a BRAF inhibitor with Omomyc, a functionally equivalent variant thereof, a conjugate comprising Omomyc or said functionally equivalent variant, a polynucleotide encoding said polypeptides, a vector comprising said polynucleotide and a cell capable of secreting the polypeptide or the conjugate. The invention also relates to pharmaceutical compositions containing the combination of the invention and to their medical uses, particularly their uses in the treatment of cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Combination Therapy with BRAF Inhibitors for Treating Cancer This invention relates to combinations of BRAF inhibitors with Omomyc, functionally equivalent variants thereof, conjugates comprising Omomyc or said functionally equivalent variants, polynucleotides encoding said polypeptides, carriers comprising said polynucleotides, and cells capable of secreting said polypeptides or said conjugates. The invention also relates to pharmaceutical compositions comprising the combinations of the invention and their pharmaceutical uses, particularly their use in the treatment of cancer. Abstract

Claims

CLAIMS1. A combination comprising: i) a first component selected from the group consisting of: a) a polypeptide comprising the sequence SEQ ID NO: 1 or a functionally equivalent variant thereof; b) a conjugate comprising a polypeptide comprising the sequence SEQ ID NO: 1 or a functionally equivalent variant thereof and a chemical moiety that facilitates cellular uptake of the polypeptide or of the functionally equivalent variant thereof; c) a polynucleotide encoding the polypeptide of a) or the conjugate of b); d) a vector comprising the polynucleotide according to c); and e) a cell capable of secreting into the medium the polypeptide according to a) or the conjugate according to b); and ii) a second component that is a BRAF inhibitor.

2. The combination according to claim 1 , wherein the first component is a polypeptide comprising the sequence SEQ ID NO: 1.

3. The combination according to claim 1 , wherein the functionally equivalent variant of SEQ ID NO: 1 is selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO; 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.

4. The combination according to any one of claims 1 or 3, wherein the chemical moiety that facilitates the cellular uptake of the polypeptide or of the functionally equivalent variant thereof is a cell-penetrating peptide sequence and wherein said cell penetrating peptide sequence and said polypeptide or functionally equivalent variant thereof form a fusion protein.

5. The combination according to any one of claims 1 or 3 to 4, wherein the conjugate additionally comprises a further nuclear localization signal.

6. The combination according to any one of claims 1 to 5, wherein the BRAF inhibitor is selected from the group consisting of dabrafenib, vemurafenib and encorafenib.

7. The combination according to claim 6, wherein the BRAF inhibitor is dabrafenib.

8. A pharmaceutical composition comprising a pharmaceutically effective amount of a combination according to any one of claims 1 to 7 and a pharmaceutically acceptable excipient.

9. A combination according to any one of claims 1 to 7 or a pharmaceutical composition according to claim 8 for use in medicine.

10. A combination according to any one of claims 1 to 7 or a pharmaceutical composition according to claim 8 for use in the prevention and / or treatment of cancer.

11. The combination or pharmaceutical composition for use according to claim 10, wherein the cancer is selected from the group consisting of melanoma, colorectal cancer and breast cancer.

12. The combination or pharmaceutical composition for use according to claim 11 , wherein the cancer is melanoma.

13. The combination or pharmaceutical composition for use according to any one of claims 10 to 12, wherein the cancer is a cancer having a BRAF mutation.

14. The combination or pharmaceutical composition for use according to any one of claims 10 to 13, wherein the cancer is a cancer resistant to BRAF inhibitors.

15. The combination or pharmaceutical composition for use according to any one of claims 9 to 14, wherein the first component is administered intravenously and the second component is administered orally.